Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTO-BLOXY: Long-term outcomes of oxygen strategies in ARDS
NCT03621293Phase 3Unknown
- Sponsor
- CHU de Besançon
- Start
- Sep 2017
- Primary completion
- Mar 2021
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxygen in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by CHU de Besançon. Primary endpoint: Diffusing Capacity of the Lungs for carbon monoxide at 6 months. Status: unknown.
02
Drugs
oxygen
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03621293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03621293.